Levonorgestrel-releasing intrauterine system - Bayer

Drug Profile

Levonorgestrel-releasing intrauterine system - Bayer

Alternative Names: Kyleena; LNG-IUS 12

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer
  • Class Hormonal replacements; Norpregnanes; Oral contraceptives; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 20 Mar 2017 Launched for Pregnancy (Prevention) in Canada (Intrauterine)
  • 14 Mar 2017 Bayer plans a phase III trial for Pregnancy (Prevention) in Russia (NCT03074045)
  • 13 Mar 2017 Phase-III clinical trials in Pregnancy (Prevention) in Russia (Intrauterine) (NCT03074045)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top